Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics

28 Jul 2023

Abstract excerpt

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) provides unique opportunities for cancer target discovery using protein expression. Proteomics data from CPTAC tumor types have been primarily generated using a multiplex tandem mass tag (TMT) approach, which is designed to provide protein quantification relative to reference samples. However, relative protein expression data are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to Advanced Proteomics Techniques and Applications
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37517589
DOI: 10.1016/j.mcpro.2023.100626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer TherapeuticsPMID 37517589Read ↗

Pan-cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer TherapeuticsSemantic proximity Read ↗

Pan-cancer proteogenomics expands the landscape of therapeutic targetsSemantic proximity Read ↗

The Target Atlas for Antibody-Drug Conjugates across Solid CancersSemantic proximity Read ↗

Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancersSemantic proximity Read ↗

High‐throughput and multi‐phases identification of autoantibodies in diagnosing early‐stage breast cancer and subtypesSemantic proximity Read ↗

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsSemantic proximity Read ↗

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancerSemantic proximity Read ↗

Profiling protein post-translational modifications in plasma-derived extracellular vesicles as fingerprints for breast cancer subtypesSemantic proximity Read ↗

Multi-omics analysis identifies BCAT2 as a potential pan-cancer biomarker for tumor progression and immune microenvironment modulationSemantic proximity Read ↗

Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879VSemantic proximity Read ↗

Bioinformatic identification of proteins with tissue-specific expression for biomarker discoverySemantic proximity Read ↗

Profiling Protein Post-Translational Modifications in Plasma-derived Extracellular Vesicles as Fingerprints for Breast Cancer SubtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.